APTAMIR Trademark

Trademark Overview


On Monday, April 10, 2023, a trademark application was filed for APTAMIR with the United States Patent and Trademark Office. The USPTO has given the APTAMIR trademark a serial number of 97880127. The federal status of this trademark filing is NON-FINAL ACTION - MAILED as of Thursday, August 1, 2024. This trademark is owned by AptamiR Therapeutics, Inc. The APTAMIR trademark is filed in the Pharmaceutical Products category with the following description:

Medicinal and biological preparations for pharmaceutical, clinical and medical treatment, namely, preparations for the modulation of gene and protein expression working at DNA transcription, RNA translation and degradation processes related thereto for the treatment of cardiovascular diseases, metabolic diseases, overweight, obesity, diabetes mellitus, dyslipidemia, liver steatosis, steatohepatitis, non-alcoholic fatty liver disease, metabolic-associated fatty liver disease, atherosclerosis, chronic visceral inflammation, ovarian cancer and related diseases and disorders.
aptamir

General Information


Serial Number97880127
Word MarkAPTAMIR
Filing DateMonday, April 10, 2023
Status641 - NON-FINAL ACTION - MAILED
Status DateThursday, August 1, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing3 - Illustration: Drawing or design which also includes word(s) / letter(s) / number(s)
Published for Opposition DateNOT AVAILABLE

Trademark Statements


Description of MarkThe mark consists of the word "APTAMIR" with the first letter "A" in black, the letters "PTA" and "I" in blue, the letter "M" in blue and black, with a blue triangle above, but touching, the letter "M", and the letter "R" in black. The color white represents background and is not a feature of the mark.
Goods and ServicesMedicinal and biological preparations for pharmaceutical, clinical and medical treatment, namely, preparations for the modulation of gene and protein expression working at DNA transcription, RNA translation and degradation processes related thereto for the treatment of cardiovascular diseases, metabolic diseases, overweight, obesity, diabetes mellitus, dyslipidemia, liver steatosis, steatohepatitis, non-alcoholic fatty liver disease, metabolic-associated fatty liver disease, atherosclerosis, chronic visceral inflammation, ovarian cancer and related diseases and disorders.
Indication of Colors claimedThe color(s) black and blue is/are claimed as a feature of the mark.

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateWednesday, May 3, 2023
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameAptamiR Therapeutics, Inc
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressNaples, FL 34119

Trademark Events


Event DateEvent Description
Thursday, April 13, 2023NEW APPLICATION ENTERED
Wednesday, May 3, 2023NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Friday, January 5, 2024ASSIGNED TO EXAMINER
Friday, January 5, 2024NON-FINAL ACTION WRITTEN
Friday, January 5, 2024NON-FINAL ACTION E-MAILED
Friday, January 5, 2024NOTIFICATION OF NON-FINAL ACTION E-MAILED
Friday, April 5, 2024APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Thursday, May 4, 2023NOTICE OF DESIGN SEARCH CODE E-MAILED
Friday, April 5, 2024APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Wednesday, July 3, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, July 3, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, July 3, 2024TEAS RESPONSE TO OFFICE ACTION RECEIVED
Thursday, August 1, 2024NOTIFICATION OF NON-FINAL ACTION E-MAILED
Thursday, August 1, 2024NON-FINAL ACTION WRITTEN
Thursday, August 1, 2024NON-FINAL ACTION E-MAILED